Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

This research is being done to evaluate if the phosphodiesterase type 5 (PDE5) inhibitor sildenafil has an effect on the frequency of recurrent priapism and the quality of life of males with sickle cell disease (SCD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Collaborator: National Institutes of Health (NIH)
• Treatments: Sildenafil Citrate

Criteria

Inclusion Criteria:

• Ages 14 to 45, inclusive

• Episodes of prolonged penile erection in the absence of sexual interest or desire, with an average frequency of at least twice weekly, when averaged over the previous four weeks

• Able to provide informed consent or assent

Exclusion Criteria:

• Use of chronic nitrates or recreational use of nitrate containing products

• Use of a PDE5 (phosphodiesterase type 5)inhibitor within the previous two weeks

• Alcohol use exceeding two standard drinks daily

• Hypersensitivity to sildenafil

• Estimated glomerular filtration rate <50ml/min

• Known cirrhosis

• Retinitis pigmentosa

• Necessary use of a P450 3A4 inhibitor (a drug which can increase plasma levels of sildenafil when taken together)